Compare Magna International Inc. Common Stock (MGA) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magna International Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Magna International Inc. Common Stock trades at $63.7 (market cap $17.04B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.82B). The key difference: Magna International Inc. Common Stock is far larger — about 4.5× Relay Therapeutics Inc. Common Stock's market cap, and Magna International Inc. Common Stock pays a 3.1% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| MGA | RLAY | |
|---|---|---|
Market Cap | $17.04B | $3.82B |
Volume | 1,523,784 | 4,332,079 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $20.75 |
52-Week Low | $43.54 | $6.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $22.08B | $2.93B |
Dividend Yield | 3.1% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Magna International Inc. Common Stock
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
